ArticleNeurochemical research2026
Ginsenoside Rb1 Inhibits Phosphorylation of Cx43 and Promotes Mitophagy To Attenuate Mouse Cerebral Ischemia/Reperfusion Injury.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting RUNX3 alleviates abdominal aortic aneurysm by ameliorating oxidative stress via mitophagy.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cerebral ischemia/reperfusion injury is a leading cause of neurological deficits, with limited treatment options available. Ginsenoside Rb1 (GRb1), a major bioactive compound of Panax ginseng, has shown neuroprotective potential. This study investigates whether GRb1 exerts its protective effects against cerebral ischemia/reperfusion injury, focusing on its effects in promoting mitophagy as the underlying mechanism. Male C57BL/6J mice underwent middle cerebral artery occlusion for 30 min followed by reperfusion. Mice were divided into four groups: Sham, Vehicle, GRb1-treated, and GRb1 combined with Mdivi-1, a mitophagy inhibitor. GRb1 (20 mg/kg) and Mdivi-1 (40 mg/kg) were administered intraperitoneally at 1 h, 12 h, and 24 h post-ischemia, followed by daily injections. Cognitive function and anxiety-like behavior were assessed using the Morris Water Maze and Open Field Test. Neuroinflammation, mitochondrial function, and connexin 43 phosphorylation were analyzed through immunofluorescence, Western blot, and ELISA. Mitophagy was evaluated by examining key markers, including PINK1, Parkin, Atg5, LC3 II, and p62. GRb1 significantly improved cognitive function and reduced anxiety-like behavior following ischemia/reperfusion injury. GRb1-treated mice exhibited decreased microglial activation and reduced levels of pro-inflammatory cytokines IL-1β and TNF-α while increasing the anti-inflammatory cytokine IL-10. Additionally, GRb1 preserved mitochondrial function by enhancing ATP production, increasing superoxide dismutase activity, and upregulating PGC1α while reducing Drp1 expression. Western blot analysis revealed that GRb1 decreased connexin 43 phosphorylation and enhanced mitophagy, as indicated by increased levels of PINK1, Parkin, Atg5, and LC3 II, with reduced p62 accumulation. Importantly, these protective effects were largely diminished when mitophagy was inhibited by Mdivi-1. GRb1 exerts its neuroprotective effects against cerebral ischemia/reperfusion injury through the activation of mitophagy. Targeting mitophagy may represent a promising therapeutic strategy for ischemic stroke and related neurological disorders.
Indexed as
Identifiers
41703332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.